Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Belangrijk jaar voor Onxeo met klinische data van DRIIV-1b (AsiDNA™ 600 mg + carboplatin + paclitaxel) in kleine kanker patiëntenpopulatie, en ook voorlopige data voor einde van het jaar van fase 2 studie AsiDNA™ + niraparib (PARPi).20-1-2020 shareholder letter It is with great pleasure that I am addressing you at the beginning of this year, after an eventful year in 2019, which Onxeo will be able to build on in 2020 to develop its key assets, notably AsiDNA™,our first tumor DNA repair inhibitor candidate at clinical stage. What can we learn from 2019? ...and what can we expect from 2020? First of all, 2019 was the year of the results of the first administration in man of AsiDNA™ by IV route. The DRIIV clinical study demonstrated the very good safety profile of AsiDNA™ and genuinely proved the mechanism of its clinical action, with the robust activation of biomarkers in tumor cells. 2019 will thus remain the year that proved that AsiDNA™ is active and very well tolerated when administered intravenously in humans. Because of its mechanism of action, AsiDNA™ is an anti-cancer agent that is particularly well suited for use in combination with other agents that “break” tumor DNA. We, therefore, chose as priority development the combination of AsiDNA™ first with chemotherapy agents, and soon with a PARP inhibitor (PARPi) (=REVOCAN). DRIIV-1b was thus initiated as soon as 2019 as the first combination study of AsiDNA™ in patients eligible carboplatin and then carboplatin + paclitaxel (DRIIV-1b) for advanced multi-treated cancers. First results are already available: a good safety profile confirmed, two of the three patients in the first group included had their disease "controlled", and tumor progression was stopped for a period longer than that of previous treatments. The study continues with additional results expected from the 1st quarter of 2020. At the same time, the preparation of REVOCAN has mobilized the R&D teams. Our objective: to demonstrate AsiDNA™'s ability to overcome the acquired resistance of tumors to niraparib (Tesaro/GSK PARPi). This study is particularly important because acquired resistance to PARPi and more generally to targeted therapies, enables the tumor to resume its progression despite treatment, after a few weeks or months, which constitutes a real hurdle today for the efficacy of these agents. Demonstrating the capability of AsiDNA™ to counteract the resistance to PARPi would position our product as a leading treatment to avoid or delay this type of resistance. On the basis of preclinical data constantly showing such an effect of AsiDNA™ in association with PARPi or other types of targeted therapies, we are ready to start REVOCAN as early as early 2020, in collaboration with a network of leading academic centers. Preliminary results are expected before year end. Finally, 2019 will also be remembered as the year of birth of OX401, sourced from our platON™ platform which is dedicated to designing agents that all share the same decoy agonist mechanism as AsiDNA™. OX401 is a next generation PARP inhibitor, which both inhibits PARP without inducing resistance and activates the STING immune pathway. This approach is the focus of a great deal of research, as it appears promising in terms of efficacy but poses real problems in terms of tolerance. From the same family as AsiDNA™, which has a good tolerance profile, OX401 could become a very promising candidate when the preclinical proof of concept is confirmed in 2020. Onxeo is thus positioned in two high-potential areas, the DNA damage response and immuno-oncology. Of course, these are only the key developments that are listed here... the tip of the iceberg. Rest assured that all teams have been and remain mobilized in 2020, in order to implement, despite a sometimes difficult environment, the elements of success that should enable us to confirm the value of our assets and the Company more broadly. On behalf of all the Onxeo teams, I thank you for your support and interest in our company, our products and our work. We look forward to keeping you informed as we move forward. With kind regards, Judith Greciet (CEO Onxeo) "Demonstrating the capability of AsiDNA™ to overcome the resistance to PARPi would position our product as a leading treatment to avoid or delay this type of resistance".www.onxeo.com/wp-content/uploads/2020... 2020 1) First efficacy signals expected from Q1 2020 (AsiDNA > DRIIV-1b) 2) Inclusion of the first patients in H1 2020, first results end 2020 (AsiDNA + niraparib > REVOCAN) 3) Preclinical proof of concept in 2020 (OX401 , a next-generation PARPi with double action) Marktwaarde van kleine €40 miljoen, weinig liquide middelen (+/-€5 miljoen) maar wel een platON™ platform wat begint te leveren, middels AsiDNA en OX401. Eigen combi-studies in toekomst kan een gouden greep blijken, afhankelijk hoe goed deze 2 therapieën werken.
Onxeo to Present Next-Generation PARP inhibitor, OX401, at PARP & DDR Inhibitors Summit 2020 The press release in PDF Paris (France), January 28, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company’s Chief Scientific Officer, Françoise Bono, will present OX401, a next-generation PARP inhibitor (PARPi) of the Company, during an oral presentation at the PARP & DDR Inhibitors Summit 2020 held in Boston, MA on January 29-30, 2020. “OX401 benefits from our accumulated insight into the unique decoy agonist mechanism already present in our clinical-stage DDR inhibitor AsiDNA™ and we are excited to present this very innovative PARP inhibitor to the world’s most recognized stakeholders in DNA Damage Response,” said Françoise Bono, Chief Scientific Officer of Onxeo. “We are in the process of building a strong preclinical data set for OX401, which was optimized to be potent on both PARP inhibition and STING response and to bypass resistance as well as homologous recombination deficiency requirements, two of the major hurdles faced by PARP inhibitors today.” OX401 is the second candidate sourced from Onxeo's proprietary platform of decoy agonists, platON™. This new compound was optimized to maintain this unique mechanism of action, while targeting other DNA-binding proteins and other mechanisms involved in tumor growth, such as the immune response. Its properties position OX401 at the crossroads of two of the most active areas in oncology, DNA Damage Response and immunotherapy. Session: Innovative Approaches to Targeting the DDR Date: Thursday, January 30, 2019 - 2:30 pm EST Location: Revere Hotel Boston Common, Boston, MA - USA Oral presentation: Introducing OX401, a Next Generation PARP Inhibitor Able to Exploit Metabolic Vulnerabilities of Cancer Cells and Inducing a Potent STING Response Introducing a ‘first-in-class’ Decoy Agonist candidate which sequesters and hyperactivates PARP Displaying selective activity in tumor cells versus healthy cells, regardless of HR status as OX401 does not induce DNA breaks or acquired resistance Exploiting a potentially synthetic lethal pathway in tumors with metabolic vulnerabilities by hyper-activating PARP and inducing NAD+ overconsumption Eliciting a potent STING response by inducing micronuclei induction
Onxeo Enters Clinical Research Agreement with Gustave Roussy to Conduct Clinical Trial of AsiDNA™ for Treatment of Relapsed Ovarian Cancer The REVOCAN phase 1b/2 study, sponsored by Gustave Roussy, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer Paris (France), January 29, 2020 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugstargeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company has entered into a Clinical Research Agreement with Gustave Roussy (“Gustave Roussy”), the leading European cancer center, to conduct the REVOCAN1 phase 1b/2 study designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib in its approved indication for 2 nd line maintenance treatment of relapsed ovarian cancer. “This is a major clinical milestone for Onxeo as we embark in this key study aiming to demonstrate that the addition of AsiDNA™ abrogates the tumor resistance to PARP inhibitors, which would in turn improve patients’ progression-free survival,” said Olivier de Beaumont, Chief Medical Officer of Onxeo. “We are excited and honored to be collaborating with Gustave Roussy, one of the world’s leading academic institutions, in a study that would open the way to AsiDNA™ becoming a must-have treatment to prevent or abrogate resistance to targeted therapies in cancer treatment.”
"Gustave Roussy and Onxeo will conduct an original proof-of-concept study of the reversion of the mechanism of resistance to a major therapeutic class. If positive, this first study, labeled by the GINECO2 group, may pave the way for further combination studies with this therapeutic class, in ovarian cancer but also in other pathologies, and offer patients who benefit from these treatments an additional opportunity to control their disease," said Patricia Pautier, MD, oncologist, head of the Gynecological Cancers Committee at Gustave Roussy and principal investigator of the study. While niraparib significantly delayed cancer progression in both patients with and without a BRCA mutation3 , treatment efficacy diminishes overtime as tumors establish new repair pathways and resist to treatment. In preclinical studies, AsiDNA™ has consistently demonstrated its capacity to prevent or abrogate the acquired resistance of the tumors to PARP inhibitors, regardless of tumor mutations. Gustave Roussy and Onxeo have collaborated on REVOCAN multi-center trial design that Gustave Roussy willsubmit, as study sponsor, to the French health authority (ANSM) and Ethics Committee in the coming weeks, with the aim to start enrolling patientsin the first semester of 2020 and obtain preliminary results before year-end.
Kunnen we weer langzaam richting de Euro? Bovenstaand nieuws lijkt me toch heel mooi.
inmiddels 8% in de plus met 2 x het gemiddeld dagvolume binnen een half uur.
Helaas weer terug bij af.
Spreekt er iemand goed Frans, voor het vertalen van dit filmpje?www.labourseetlavie.com/strategie-et-...
Ik ben de Franse taal niet machtig C200. Wat ik verder nog wel interessant vindt aangaande Onxeo: ze zoeken actief naar partnership voor AsiDNA. Zie investor meeting januari 2020 pagina 25-28 voor de outlook en bewoordingen als 'ready for partnership' & 'ready for licensing'.www.onxeo.com/wp-content/uploads/2020... Klinische data van DRIIV-1b in Q1 2020 kan belangrijke doorbraak betekenen al is patiëntenpopulatie van zes zeer beperkt. Gezien grote huidige markt voor PARPi, en mogelijkheden combi AsiDNA, kan een partnership veel betekenen. Wel belangrijk dat dit een grote oncologie-speler is. Eerdere samenwerking met Spectrum was een farce. Met tevens een next generatie PARPi in preklinische ontwikkeling heeft Onxeo nog genoeg te bieden. De urgentie is wel zeer hoog gezien slinkende liquide positie.
Dank WIC32, De liquide positie baart mij inderdaad zorgen. Als er nieuw geld aangetrokken moet worden kan dit de koers hard doen dalen. Ik blijf dan ook zeer beperkt in Onxeo maar het blijft een interessant bedrijf.
Afwachten of het aandeel hogere bodems en toppen gaat laten zien. Als laatste low 0,50. En high 0,663.
voorlopig toch nog niet..
11-2-2020 ONXEO ENTERS INTO SETTLEMENT AGREEMENT WITH SPEPHARM AND SPEBIO > Settlement agreement fully resolves long-lasting litigation between the parties and all related proceedings > Settlement terms have no impact on Onxeo’s expected cash runway Paris (France), February 11, 2020 – 7:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces it has entered into an agreement to settle (“the Settlement Agreement”) the remaining actions in the litigation which began in 2009 between Onxeo on the one hand and SpePharm and SpeBio B.V. on the other hand. SpeBio B.V. is a joint-venture managed by SpePharm, which was dedicated to the distribution in Europe of Loramyc®, a product sold by Onxeo to Vectans Pharma in July 2017. Two remaining actions were pending following the decision of the Paris Court of Appeal in December 2018. On the one hand, Onxeo had appealed this decision before the French Supreme Court. On the other hand, the proceedings before the Court of Arbitration of the International Chamber of Commerce (ICC), which had been suspended whilst awaiting the decision of the French Courts, had resumed. The Settlement Agreement includes immediate complete and final withdrawal of these last two pending actions as well as any and all future claims or causes of action between the parties linked to their previous disputes. In return, Onxeo immediately sells its shares in SpeBio to SpePharm at their nominal value, thereby transferring its share of the cash of the joint venture amounting to approximately €3.5m and will pay 15 to 20% of net cash received on future commercial agreements concerning Onxeo’s R&D assets for a total cumulative amount of €6m within the next 4 years. As SpeBio’s cash was not taken into account in Onxeo’s cash position, the Settlement Agreement’s terms have no impact on the Company’s cash runway of Q3 2020, nor on Onxeo’s current operational plan. This agreement settles a dispute which had no more relation to the Company’s current activities and strategy and will enable the Company to focus on the development of its assets in the field of DNA Damage Response. Accounting impacts The signing of this agreement after the end of the 2019 financial year will result in the recognition of the following provisions in the consolidated accounts at December 31, 2019: - A provision for depreciation of equity securities in the amount of 3.6 million euros, as a result of the sale of SpeBio shares at their nominal value. - A provision for risks of 6 million euros, corresponding to the additional payments linked to the Group's future license agreements. The total charge will be booked under “other operating income and expenses”.www.onxeo.com/onxeo-enters-into-settl...
3 aspecten omtrent bovenstaand persbericht: 1) onzekerheid over cash-impact behoort tot het verleden. Deze overeenkomst kost indirect geld, echter vindt er nu geen uitstroom van cash plaats. 2) Onxeo heeft geen recht meer op deel cash van SpeBio B.V. Het aandeel betrof €3,5 miljoen 3) Komende 4 jaar, gerekend vanaf 11-2-2020 m.i., is Onxeo nog maximaal €6 miljoen verschuldigd aan SpePharm, inhoudende 15-20% van netto geld wat Onxeo realiseert middels toekomstige commerciële overeenkomsten aangaande R&D moleculen (AsiDNA en OX401). Dit omhelst dus partnerships/in-licentiename t.b.v. toekomstige commercialisatie. Gisteren negatieve reactie; vandaag sterk positieve reactie van de koers. Liquide middelen nog goed voor max. 7 maanden. Eens zien wat het management gaat klaarspelen omtrent partnership. Het is 5 voor 12, maar moleculen bieden veel combi-mogelijkheden voor kankertherapieën dus neem aan dat de opties goed zijn verkend.
Woman in Chains32 schreef op 13 februari 2020 12:53 :
Het is 5 voor 12, maar moleculen bieden veel combi-mogelijkheden voor kankertherapieën dus neem aan dat de opties goed zijn verkend.
Dank voor de duiding! Ik hoop dat je gelijk hebt vwb je laatste opmerking; dit is wel een moment voor het management om zich te bewijzen.
Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces that the Company will present first preclinical results on OX401, its next-generation PARP inhibitor (PARPi), during a poster session at the ESMO-TAT1 Congress 2020 dedicated to the research on targeted cancer therapies, to be held in Paris, France, on March 2-4, 2020. “Based on our proprietary platform platON™, OX401 benefits from our accumulated experience on the original decoy agonist mechanism that it shares with AsiDNA™, our clinical-stage DDR inhibitor. We are excited to present the first results on OX401, including its high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells,” said Françoise Bono, Chief Scientific Officer of Onxeo. “These data establish OX401 in the current cutting-edge areas of research and open up promising therapeutic prospects, by exploiting both its ability to exhaust the tumor cell without inducing resistance and its value in combination with immunotherapies.” OX401 is the second candidate sourced from Onxeo’s proprietary platform of decoy agonists, platON™. It was optimized to maintain this unique mechanism of action, while specifically targeting PARP and immune response. Its properties position OX401 at the crossroads of two of the most active areas in oncology, DNA damage repair and immunotherapy. Poster presentation: OX401, a new generation of PARP interfering drug for cancer treatment Poster ID: 21P (ID 224) Date: Monday, March 2, 2020 - 5:30 pm CET Location: Palais des congrès – Place de la porte Maillot – Paris (France) - Hall Bordeaux
Al die lappen Engels lezen vind ik lastig. Is er ook een korte bondige Nederlandse samenvatting? Onxeo zou eens iets moeten hebben tegen het Coronavirus en honderden procenten omhoog schieten :-)
RW1963 schreef op 28 februari 2020 14:09 :
Al die lappen Engels lezen vind ik lastig.
Is er ook een korte bondige Nederlandse samenvatting?
Onxeo zou eens iets moeten hebben tegen het Coronavirus en honderden procenten omhoog schieten :-)
Ze zijn actief in een andere tak van sport. Maar de bedrijven die in die richting werken doen hun best. Ik heb gisteren 2 namen van bedrijven gepost die zelf in ieder geval vinden dat ze goed op weg zijn.
RW1963 schreef op 28 februari 2020 14:09 :
Al die lappen Engels lezen vind ik lastig.
Is er ook een korte bondige Nederlandse samenvatting?
Onxeo zou eens iets moeten hebben tegen het Coronavirus en honderden procenten omhoog schieten :-)
Hier is de aanleiding voor het pb: today announces that the Company will... present... first preclinical results on OX401,... its... next-generation... PARP inhibitor (PARPi),... during a poster session at the... ESMO-TAT1 Congress 2020 ...dedicated to the research on targeted cancer therapies, to be held in... Paris, France,... on... March 2-4, 2020... Daar ontmoeten ze elkaar, en kunnen misschien zaken doen;)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee